Biosimilar injectables specialist Hospira has been ordered to pay $70 million for infringing a patent belonging to Amgen (Nasdaq: AMGN) relating to the anemia treatment Epogen (epoetin alfa).
Amgen launched the suit more than two years ago, alleging that Hospira had violated information-sharing and advance-notice provisions of the Biologics Price Competition and Innovation Act (BPCIA) in developing its biosimilar.
The US biotech major argued that Hospira had not respected the BPCIA provision, known as the patent dance, by holding back information on manufacturing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze